RxDoctor Payments Data

Vishal Sawhney, MD

Pulmonary Disease · Canton, OHNPI 1164622247

Payments from drug & device makers

$53,496in general payments, 2019–2025

Across 841 payments — averaging $63.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$22K
  • AstraZeneca$17K
  • Actelion Pharmaceuticals, Ltd$4K
  • GSK$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Boehringer Ingelheim$1K
  • plus $6K from 44 others

What the payments were for

  • Speaking & faculty fees$34,83070%
  • Travel & lodging$1,1562%
  • Food & beverage$13,41327%
  • Education$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,496 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$96,526
Medicare patients
491
Services billed
873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter814$662,806
OpsumitMacitentan47$589,069
OfevNintedanib Esylate42$528,840
UptraviSelexipag12$272,489
Breztri AerosphereBudesonide/Glycopyr/Formoterol340$253,690
Breo ElliptaFluticasone/Vilanterol395$211,050
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr284$182,694
AdempasRiociguat12$169,052
Spiriva RespimatTiotropium Bromide200$150,119
Prolastin CAlpha-1-Proteinase Inhibitor11$145,305
Stiolto RespimatTiotropium Br/Olodaterol Hcl204$133,919
Ambrisentan17$89,767
XareltoRivaroxaban103$69,514
SymbicortBudesonide/Formoterol Fumarate153$50,837
Pirfenidone13$44,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$2,131$1,077,7731,556 claims
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,066$861,55859 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,019$812,877446 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Daliresp$16,918$337,836565 claims
BayerAdempas$172$169,05212 claims
Grifols USA, LLCProlastin C$430$145,30511 claims
Johnson & JohnsonXarelto$22,325$69,514103 claims
MerckDulera$171$6,77320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →